{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:27:56Z","timestamp":1783636076037,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Clinical Research Projects of National Clinical Research Center for Interventional Medicine","award":["2021-006"],"award-info":[{"award-number":["2021-006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The efficacy and validity of excimer laser ablation (ELA) in the in-stent restenosis (ISR) has been confirmed. However, its application in de novo atherosclerotic lesions of lower extremity artery disease (LEAD) has not been clearly defined and its procedure has not been standardized.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ELABORATE is a prospective, multicenter, real-world study designed to evaluate the efficacy and safety between ELA combined with drug-coated balloon (DCB) and DCB alone in de novo atherosclerotic lesions of LEAD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>ELABORATE is a prospective, multicenter, real-world study designed to assess the efficacy and safety between ELA combined with drug-coated balloon (DCB) and DCB alone in patients with de novo atherosclerotic lesions of LEAD. According to the real-world situation, eligible patients will be allocated to ELA\u2009+\u2009DCB group (group E) and DCB group (group C). Baseline and follow-up information (at 3, 6, and 12\u00a0months) will be collected. The primary efficacy point is primary patency at 12-months, and the secondary efficacy points include clinically driven target lesion reintervention (CD-TLR), change of Rutherford class, ankle-brachial index and ulcer healing rate. These indexes will be assessed and recorded at 3, 6, and 12-month follow-up. Also, safety evaluation, including major adverse event, all-cause mortality through 30-day follow-up, unplanned major amputation, bailout stent and distal embolization, will also be evaluated by an independent core laboratory. All the data will be collected and recorded by the electric data capture system. This study will be finished in 3\u00a0years and the 12-month results will be available in 2023. All the patients will be followed for 5\u00a0years.<\/jats:p>\n                <jats:p><jats:italic>Trial registration number<\/jats:italic> Chinese Clinical Trial Registry (ChiCTR2100051263). Registered 17 September 2019. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/listbycreater.aspx\">http:\/\/www.chictr.org.cn\/listbycreater.aspx<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02751-1","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T09:03:14Z","timestamp":1657962194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Excimer laser ablation combined with drug-coated balloon versus drug-coated balloon in the treatment of de novo atherosclerotic lesions in lower extremities (ELABORATE): study protocol for a real-world clinical trial"],"prefix":"10.1186","volume":"22","clinical-trial-number":[{"clinical-trial-number":"chictr2100051263","registry":"10.18810\/chictr"}],"author":[{"given":"Xiaolang","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyu","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changpo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3754-2458","authenticated-orcid":false,"given":"Zhihui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,16]]},"reference":[{"issue":"2","key":"2751_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1024\/0301-1526\/a000603","volume":"46","author":"H Lawall","year":"2017","unstructured":"Lawall H, Huppert P, Espinola-Klein C, Zemmrich CS, Ruemenapf G. German guideline on the diagnosis and treatment of peripheral artery disease\u2014a comprehensive update 2016. Vasa. 2017;46(2):79\u201386.","journal-title":"Vasa"},{"issue":"1","key":"2751_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0021-9150(03)00204-1","volume":"172","author":"C Diehm","year":"2004","unstructured":"Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004;172(1):95\u2013105.","journal-title":"Atherosclerosis"},{"issue":"9901","key":"2751_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FG Fowkes","year":"2013","unstructured":"Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329\u201340.","journal-title":"Lancet"},{"issue":"1","key":"2751_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejvs.2006.11.008","volume":"33","author":"DJ Adam","year":"2007","unstructured":"Adam DJ, Bradbury AW. TASC II document on the management of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2007;33(1):1\u20132.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"2751_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1358863X08089277","volume":"13","author":"AT Hirsch","year":"2008","unstructured":"Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the medicare population. Vasc Med. 2008;13(3):209\u201315.","journal-title":"Vasc Med"},{"issue":"12","key":"2751_CR6","first-page":"e686","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(12):e686\u2013725.","journal-title":"Circulation"},{"issue":"6","key":"2751_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1056\/NEJM199202063260605","volume":"326","author":"MH Criqui","year":"1992","unstructured":"Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381\u20136.","journal-title":"N Engl J Med"},{"key":"2751_CR8","doi-asserted-by":"crossref","unstructured":"Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19(1):1\u20139.","DOI":"10.1583\/11-3627.1"},{"issue":"18","key":"2751_CR9","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa051303","volume":"354","author":"M Schillinger","year":"2006","unstructured":"Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879\u201388.","journal-title":"N Engl J Med"},{"issue":"3","key":"2751_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/CIRCULATIONAHA.107.689141","volume":"116","author":"H Krankenberg","year":"2007","unstructured":"Krankenberg H, Schluter M, Steinkamp HJ, B\u00fcrgelin K, Scheinert D, Schulte KL, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116(3):285\u201392.","journal-title":"Circulation"},{"issue":"12","key":"2751_CR11","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1161\/CIRCULATIONAHA.107.688341","volume":"115","author":"M Schillinger","year":"2007","unstructured":"Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115(12):2745\u20139.","journal-title":"Circulation"},{"issue":"3","key":"2751_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/CIRCINTERVENTIONS.109.903468","volume":"3","author":"JR Laird","year":"2010","unstructured":"Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267\u201376.","journal-title":"Circ Cardiovasc Interv"},{"issue":"6","key":"2751_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1583\/05-1704.1","volume":"13","author":"SH Duda","year":"2006","unstructured":"Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13(6):701\u201310.","journal-title":"J Endovasc Ther"},{"issue":"6","key":"2751_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/CIRCINTERVENTIONS.112.971630","volume":"5","author":"M Werk","year":"2012","unstructured":"Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831\u201340.","journal-title":"Circ Cardiovasc Interv"},{"issue":"7","key":"2751_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa0706356","volume":"358","author":"G Tepe","year":"2008","unstructured":"Tepe G, Zeller T, Albrecht T, Heller S, Schwarzw\u00e4lder U, Beregi JP, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689\u201399.","journal-title":"N Engl J Med"},{"issue":"1","key":"2751_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcin.2013.05.022","volume":"7","author":"D Scheinert","year":"2014","unstructured":"Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. J Am Coll Cardiol Intv. 2014;7(1):10\u20139.","journal-title":"J Am Coll Cardiol Intv"},{"issue":"18","key":"2751_CR17","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.jacc.2012.07.033","volume":"60","author":"E Stabile","year":"2012","unstructured":"Stabile E, Virga V, Salemme L, Cioppa A, Ambrosini V, Sorropago G, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60(18):1739\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2751_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1583\/13-4420R.1","volume":"21","author":"F Liistro","year":"2014","unstructured":"Liistro F, Angioli P, Porto I, Ricci L, Ducci K, Grotti S, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther. 2014;21(1):1\u20138.","journal-title":"J Endovasc Ther"},{"issue":"5","key":"2751_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/1526602815600156","volume":"22","author":"G Tepe","year":"2015","unstructured":"Tepe G, Beschorner U, Ruether C, Fischer I, Pfaffinger P, Noory E, et al. Drug-eluting balloon therapy for femoropopliteal occlusive disease: predictors of outcome with a special emphasis on calcium. J Endovasc Ther. 2015;22(5):727\u201333.","journal-title":"J Endovasc Ther"},{"key":"2751_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.avsg.2019.06.038","volume":"62","author":"EM San Norberto","year":"2020","unstructured":"San Norberto EM, Flota CM, Fidalgo-Domingos L, Taylor JH, Vaquero C. Real-world results of supera stent implantation for popliteal artery atherosclerotic lesions: 3-year outcome. Ann Vasc Surg. 2020;62:397\u2013405.","journal-title":"Ann Vasc Surg"},{"issue":"1","key":"2751_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejvs.2005.09.006","volume":"31","author":"N Diehm","year":"2006","unstructured":"Diehm N, Shan A, Silvestro A, Do DD, Dick F, Schmidli J, et al. Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc Endovasc Surg. 2006;31(1):59\u201363.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"2 suppl","key":"2751_CR22","first-page":"I70","volume":"83","author":"P Capek","year":"1991","unstructured":"Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation. 1991;83(2 suppl):I70-80.","journal-title":"Circulation"},{"issue":"1 Pt A","key":"2751_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jcin.2014.09.009","volume":"8","author":"EJ Dippel","year":"2015","unstructured":"Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015;8(1 Pt A):92\u2013101.","journal-title":"JACC Cardiovasc Interv"},{"key":"2751_CR24","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"key":"2751_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/15266028221092979","author":"X Jiang","year":"2022","unstructured":"Jiang X, Ju S, Chen B, Jiang J, Shi Y, Ma T, et al. Safety and effectiveness of excimer laser ablation combined with drug-coated balloon for atherosclerotic obliterans in the lower extremity. J Endovasc Ther. 2022. https:\/\/doi.org\/10.1177\/15266028221092979.","journal-title":"J Endovasc Ther"},{"issue":"6","key":"2751_CR26","doi-asserted-by":"publisher","first-page":"E212","DOI":"10.1002\/ccd.25387","volume":"83","author":"KJ Rocha-Singh","year":"2014","unstructured":"Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83(6):E212\u201320.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"2751_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1583\/08-2642.1","volume":"16","author":"NW Shammas","year":"2009","unstructured":"Shammas NW, Coiner D, Shammas GA, Christensen L, Dippel EJ, Jerin M. Distal embolic event protection using excimer laser ablation in peripheral vascular interventions: results of the DEEP EMBOLI registry. J Endovasc Ther. 2009;16(2):197\u2013202.","journal-title":"J Endovasc Ther"},{"key":"2751_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1745-6215-15-63","volume":"15","author":"T Zeller","year":"2014","unstructured":"Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, et al. IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial. Trials. 2014;15:63.","journal-title":"Trials"},{"issue":"18","key":"2751_CR29","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.jcin.2016.06.055","volume":"9","author":"X Jia","year":"2016","unstructured":"Jia X, Zhang J, Zhuang B, Fu W, Wu D, Wang F, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Interv. 2016;9(18):1941\u20139.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"2751_CR30","doi-asserted-by":"publisher","first-page":"e037879","DOI":"10.1136\/bmjopen-2020-037879","volume":"10","author":"S Chen","year":"2020","unstructured":"Chen S, Xu Z, Liu H, Zhang Y, Zhang J, Chen Y, et al. Perioperative patient-controlled regional analgesia versus patient-controlled intravenous analgesia for patients with critical limb ischaemia: a study protocol for a randomised controlled trial. BMJ Open. 2020;10(10):e037879.","journal-title":"BMJ Open"},{"issue":"3","key":"2751_CR31","first-page":"359","volume":"54","author":"C Wissgott","year":"2013","unstructured":"Wissgott C, Kamusella P, Ludtke C, Andresen R. Excimer laser atherectomy after unsuccessful angioplasty of TASC C and D lesions in femoropopliteal arteries. J Cardiovasc Surg (Torino). 2013;54(3):359\u201365.","journal-title":"J Cardiovasc Surg (Torino)"},{"issue":"6","key":"2751_CR32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s11882-011-0222-7","volume":"11","author":"D Price","year":"2011","unstructured":"Price D, Chisholm A, van der Molen T, Roche N, Hillyer EV, Bousquet J. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep. 2011;11(6):526\u201338.","journal-title":"Curr Allergy Asthma Rep"},{"key":"2751_CR33","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1513\/AnnalsATS.201309-300RM","volume":"11","author":"N Roche","year":"2014","unstructured":"Roche N, Reddel H, Martin R, Brusselle G, Papi A, Thomas M, et al. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc. 2014;11:S99-104.","journal-title":"Ann Am Thorac Soc"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02751-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02751-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02751-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T09:04:27Z","timestamp":1657962267000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02751-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2751"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02751-1","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,16]]},"assertion":[{"value":"20 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be conducted in accordance with the ethical principles of the Declaration of Helsinki. The study is approved by Ethical Review Board of Zhongshan Hospital, Fudan University (B2021-578). All patients will provide written consent for participation and publication of trial data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. Meanwhile, the study funders have no role in in study design, collection, management, analysis, or interpretation of data, writing of the report, or the decision to submit the report for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}